Insights from the Early TAVR Trial at SCAI 2025

At SCAI Scientific Sessions 2025 in Washington, DC, Lyndon C. Box, MD, FSCAI, sat down with Molly Szerlip, MD, FSCAI, co-author of the New England Journal of Medicine Early TAVR Trial to break down the results. With new FDA approval for TAVR in this population, Dr. Szerlip emphasized the importance of referring all severe AS patients to the heart team—regardless of symptoms—for timely evaluation and treatment.

https://scai.org/early-tavr-trial-tra...